Pharmaceutical compositions for treating pain

Abstract

The present invention discloses a novel use of a pharmaceutical composition in the preparation of a medicament in the treatment of opioid-induced tolerance and addiction, in particular to the use of AC1 inhibitor NB001 and AC1&8 mixed inhibitors NB010 and NB011 in the preparation of a medicament in the treatment of opioid-induced tolerance and addiction.

I claim: 
     
         1 . A pharmaceutical composition for treating pain, comprising:
 opioids, and   at least one selected fro the group consisting of NB001, NB010, or NB011,   the NB001, i.e., 5-((2-(6-amino-9H-purin-9-yl)ethyl)amino)pentane-1-ol, has the following structure:   
       
         
           
           
               
               
           
         
         the NB010, i.e., 6-amino-9-(2-p-methoxy-ethyl)-9H-purine-8-thiol, has the following chemical structure: 
       
       
         
           
           
               
               
           
         
         the NB011, i.e., 4-(9H-purin-6-yl)morpholine (also known as 6-morpholin-4-yl-7H-purine) has the following chemical structure: 
       
       
         
           
           
               
               
           
         
       
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the opioids is morphine. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein the three compounds of NB001, NB010, or NB011 further comprises a pharmaceutically acceptable salt or solvate thereof. 
     
     
         4 . Use of a pharmaceutical composition for preparing a medicament in the treatment of pain, the pharmaceutical composition comprising: opioids, and
 at least one selected from the group consisting of NB001, NB010, or NB011,   the NB001, i.e., 5-((2-(6-amino-9H-purin-9-yl)ethyl)amino)pentane-1-ol, has the following structure:   
       
         
           
           
               
               
           
         
         the NB010, i.e., 6-amino-9-(2-p-methoxy-ethyl)-9H-purine-8-thiol, has the following chemical structure: 
       
       
         
           
           
               
               
           
         
         the NB011, i.e., 4-(9H-purin-6-yl)morpholine (also known as 6-morpholin-4-yl-7H-purine) has the following chemical structure: 
       
       
         
           
           
               
               
           
         
       
     
     
         5 . The pharmaceutical composition according to  claim 4 , wherein the opioids is morphine. 
     
     
         6 . The pharmaceutical composition according to  claim 4 , wherein the three compounds of NB001, NB010, or NB011 further comprises a pharmaceutically acceptable salt or solvate thereof. 
     
     
         7 . A method for treating pain, wherein applying opioids, in combination with, at least one selected from the group consisting of NB001, NB010, or NB011, and a pharmaceutically acceptable salt or solvates thereof,
 the NB001, i.e., 5-((2-(6-amino-9H-purin-9-yl)ethyl)amino)pentane-1-ol, has the following structure:   
       
         
           
           
               
               
           
         
         the NB010 i.e., 6-amino-9-(2-p-methoxy-ethyl-9H purine-8-thiol, has the following chemical structure: 
       
       
         
           
           
               
               
           
         
         the NB011, i.e., 4-(9H-purin-6-yl)morpholine (also known as 6-morpholin-4-yl-7H-purine) has the following chemical structure: 
       
       
         
           
           
               
               
           
         
       
     
     
         8 . A pharmaceutical composition for treating anxiety caused by neuropathic pain and anxiety and depression associated with other diseases, the pharmaceutical composition containing at least one of three compounds of NB001, NB010, or NB011. 
     
     
         9 . The pharmaceutical composition according to  claim 8 , the three compounds of NB001, NB010, or NB011 further comprises a pharmaceutically acceptable salt or solvate thereof. 
     
     
         10 . A pharmaceutical composition for treating chronic visceral pain and related anxiety and depression, the pharmaceutical composition containing at least one of three compounds of NB001, NB010, or NB011. 
     
     
         11 . A pharmaceutical composition for treating an itching response caused by chronic use of morphine, the pharmaceutical composition containing at least one of three compounds of NB001, NB010, or NB011.